Teniposide

In the US, Teniposide (teniposide systemic) is a member of the drug class mitotic inhibitors and is used to treat Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia and Non-Hodgkin's Lymphoma.

US matches:

• Teniposide


• Teniposide Intravenous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01CB02

CAS registry number (Chemical Abstracts Service)

0029767-20-2

Chemical Formula

C32-H32-O13-S

Molecular Weight

656

Therapeutic Category

Antineoplastic agent, antimitotic

Chemical Name

4'-Demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-ß-D-glucopyranoside)

Foreign Names

• Teniposidum (Latin)
• Teniposid (German)
• Téniposide (French)
• Teniposido (Spanish)

Generic Names

• Teniposide (OS: BAN, DCIT, USAN)
• Téniposide (OS: DCF)
• Epidophyllotoxin (IS)
• EPT (IS)
• PGT (IS)
• VM 26 (IS)

Brand Names

• Vumon
  Bristol-Myers Squibb, Argentina; Bristol-Myers Squibb, Australia; Bristol-Myers Squibb, Brazil; Bristol-Myers Squibb, Canada; Bristol-Myers Squibb, Chile; Bristol-Myers Squibb, China; Bristol-Myers Squibb, Spain; Bristol-Myers Squibb, Hong Kong; Bristol-Myers Squibb, Italy; Bristol-Myers Squibb, Luxembourg; Bristol-Myers Squibb, Netherlands; Bristol-Myers Squibb, New Zealand; Bristol-Myers Squibb, Poland; Bristol-Myers Squibb, United States

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.